Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-γ agonist use in prediabetes

被引:10
|
作者
Kavanagh, Kylie [1 ]
Brown, Kathleen K. [2 ]
Berquist, Mandy L. [2 ]
Zhang, Li [1 ]
Wagner, Janice D. [1 ]
机构
[1] Wake Forest Univ, Comparat Med Sect, Dept Pathol, Sch Med, Winston Salem, NC 27127 USA
[2] GlaxoSmithKline, Res Triangle Pk, NC USA
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2010年 / 59卷 / 06期
基金
美国国家卫生研究院;
关键词
LOWERS BLOOD-PRESSURE; PPAR-GAMMA; INSULIN SENSITIVITY; FAT DISTRIBUTION; BODY-WATER; ROSIGLITAZONE; RETENTION; VOLUME; THIAZOLIDINEDIONES; EXPRESSION;
D O I
10.1016/j.metabol.2010.02.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pioglitazone is prescribed to improve insulin sensitivity in type 2 diabetes mellitus patients and has been discussed as a therapy for metabolic syndrome. Pioglitazone and other thiazolidinediones are associated with fluid retention and edema that may exacerbate existing or developing congestive heart failure, which is often present in these patients. Using a nonhuman primate model, our aims were to evaluate (1) whether fluid shifts were detectable in normoglycemic monkeys, (2) which fluid compartment changed, and (3) whether fluid retention was dose dependent. Seventeen adult male cynomolgus macaques (Macaca fascicularis) were studied in a Latin square design such that all animals received 0, 1, 2, and 5 mg/kg pioglitazone for 6 weeks with 2 weeks of washout between dosing intervals. Doses approximated human exposures achieved with 30, 45, and 60 mg. At the end of each period, animals were weighed and underwent dual-absorption x-ray absorption scanning for body composition measurements. Fluid volumes were quantitated by Evans blue dilution for plasma volume, equilibration of sodium bromide for extracellular water, and deuterated water for total body water. Significant (P < .05) effects were seen with expansion of PV at both the 2- and 5-mg/kg doses, along with reduced plasma sodium at 5 mg/kg; however, surrogate end points used to indicate fluid retention (body weight, hematocrit, total protein, and albumin) did not change significantly. Significant trends toward increases in interstitial fluid and extracellular water with increasing dose were apparent. Pioglitazone effectively improved metabolic status by significantly decreasing fasting glucose and triglycerides and increasing adiponectin. We conclude that thiazolidinedione-related plasma volume expansion occurs in nondiabetic primates and that fluid retention is detectable when compartments are directly measured. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:914 / 920
页数:7
相关论文
共 50 条
  • [1] The peroxisome proliferator-activated receptor-γ agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-α- dependent manner in vitro and in vivo in mice
    Orasanu, Gabriela
    Ziouzenkova, Ouliana
    Devchand, Pallavi R.
    Nehra, Vedika
    Hamdy, Osama
    Horton, Edward S.
    Plutzky, Jorge
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (10) : 869 - 881
  • [2] Peroxisome proliferator-activated receptor-γ agonist pioglitazone suppresses experimental autoimmune uveitis
    Okunuki, Yoko
    Usui, Yoshihiko
    Nakagawa, Hayate
    Tajima, Kazuki
    Matsuda, Ryusaku
    Ueda, Shunichiro
    Hattori, Takaaki
    Kezuka, Takeshi
    Goto, Hiroshi
    [J]. EXPERIMENTAL EYE RESEARCH, 2013, 116 : 291 - 297
  • [3] CIS-DICHLORODIAMMINEPLATINUM UPREGULATES THE EXPRESSION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-γ AND ENHANCES THE CYTOTOXICITY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-γ AGONIST
    Tanaka, Nobuyuki
    Miyajima, Akira
    Hasegawa, Masanori
    Shirotake, Suguru
    Kosaka, Takeo
    Kikuchi, Eiji
    Oya, Mototsugu
    [J]. JOURNAL OF UROLOGY, 2010, 183 (04): : E379 - E379
  • [4] Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, reduces the progression of experimental osteoarthritis in guinea pigs
    Kobayashi, T
    Notoya, K
    Naito, T
    Unno, S
    Nakamura, A
    Martel-Pelletier, J
    Pelletier, JP
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (02): : 479 - 487
  • [5] Inhibition of corneal neovacularization by pioglitazone, a peroxisome proliferator-activated receptor-γ ligand
    Sarayba, MA
    Li, L
    Tungsiripat, T
    Liu, NH
    Sweet, PM
    Sanchez, JA
    Patel, AJ
    Osann, KE
    Pershadsingh, HA
    Chuck, RS
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U399 - U399
  • [6] Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates myocardial ischernia/reperfusion injury in a rat model
    Ito, H
    Nakano, A
    Kinoshita, M
    Matsumori, A
    [J]. LABORATORY INVESTIGATION, 2003, 83 (12) : 1715 - 1721
  • [7] Renal-Protective Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone in ob/ob Mice
    Li, Ying
    Xia, Tian
    Li, Rong
    Tse, Gary
    Liu, Tong
    Li, Guangping
    [J]. MEDICAL SCIENCE MONITOR, 2019, 25 : 1582 - 1589
  • [8] Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-γ, pioglitazone
    Enomoto, N
    Takei, Y
    Hirose, M
    Konno, A
    Shibuya, T
    Matsuyama, S
    Suzuki, S
    Ikejima, K
    Kitamura, T
    Sato, N
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 306 (03): : 846 - 854
  • [9] Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease
    Breidert, T
    Callebert, J
    Heneka, MT
    Landreth, G
    Launay, JM
    Hirsch, EC
    [J]. JOURNAL OF NEUROCHEMISTRY, 2002, 82 (03) : 615 - 624
  • [10] Fenofibrate, a peroxisome proliferator-activated receptor-α agonist, exerts anticonvulsive properties
    Porta, Natacha
    Vallee, Louis
    Lecointe, Cecile
    Bouchaert, Emmanuel
    Staels, Bart
    Bordet, Regis
    Auvin, Stephane
    [J]. EPILEPSIA, 2009, 50 (04) : 943 - 948